Based on similarities between HMGB1 and HMGB2, we hypothesize that astrocytomas with high HMGB2 expression have a more powerful immune response to damage-associated molecular patterns (DAMPs), arising after RT plus temozolomide and/or oncolytic viral vectors injection [58]. The gene discussed is HMGB1; the disease is astrocytoma (excluding glioblastoma).